An ongoing clinical trial has shown that the use of a recently approved hepatitis C virus (HCV) medication could make it possible to transplant HCV-infected kidneys into non-infected patients.
An ongoing clinical trial has shown that the use of a recently approved hepatitis C virus (HCV) medication could make it possible to transplant HCV-infected kidneys into non-infected patients. The trial conducted by Penn Medicine aims to determine the safety and efficacy of this new approach, which could make hundreds more kidneys available for transplant per year.
Under current regulations, organs from deceased donors with HCV can only be transplanted into other HCV-positive recipients, resulting in the majority of these organs being discarded. The researchers in this study estimate that if the trial is successful and HCV-infected kidneys are allowed to be used, then more than 500 additional patients a year could receive a desperately needed kidney.
The first participant in the study, who had been on the transplant waiting list for more than 5 years, received an infected kidney in July 2016. After a full course of the new HCV-eradicating medication Zepatier, her blood shows no evidence of the virus, inspiring hope for many patients in need of a transplant.
In the initial stage of the trial, researchers will give the transplant and treatment regimen to 10 patients. The kidneys used for these transplants are held to higher standards of quality and must only be infected with HCV genotype 1, the strain that is most successfully cured by this medication.
“While these kidney quality criteria may be more selective than our usual approach to choosing organs, we are aiming to evaluate safety and efficacy in only the most viable organs in this initial pilot phase of the clinical trial,” explained David S. Goldberg, MD, MSCE, one of the researchers leading the trial.
Participants in this study must undergo a thorough informed consent process to ensure they understand that they are at risk of contracting HCV if the medication fails. As these patients have been undergoing chronic dialysis for months or even years with little hope of finding a donor, many of them are willing to take that chance.
In a study published in The American Journal of Managed Care’s HCV special issue, researchers had anticipated that new HCV treatments could alleviate some of the need for transplants by preventing liver failure in patients with the virus, thus eliminating the infected person’s need for a transplanted organ. This clinical trial shows that effective treatment with new medications not only makes patients with HCV less likely to be organ recipients, but it actually allows them the possibility of becoming donors after their death.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More